Zimmer Biomet (NYSE:ZBH) Stock Rating Upgraded by Barclays

Posted by Brian Himes on Oct 9th, 2026

Zimmer Biomet (NYSE:ZBH – Get Free Report) was upgraded by equities researchers at Barclays to a “hold” rating in a report released on Wednesday, Zacks reports.

ZBH has been the topic of several other research reports. Truist Financial upped their price target on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Stifel Nicolaus lifted their price objective on Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a research report on Thursday, August 6th. Royal Bank Of Canada upped their target price on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Zimmer Biomet in a research report on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $103.33.

View Our Latest Stock Analysis on Zimmer Biomet

Zimmer Biomet Trading Up 0.5%

Shares of ZBH opened at $88.96 on Wednesday. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $106.88. The stock has a market cap of $16.97 billion, a PE ratio of 21.65, a P/E/G ratio of 1.67 and a beta of 0.49. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The business’s 50-day moving average price is $95.80 and its 200-day moving average price is $91.13.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the business earned $2.07 earnings per share. Zimmer Biomet’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts forecast that Zimmer Biomet will post 8.54 EPS for the current fiscal year.

Insider Buying and Selling

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Chad Phipps sold 3,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors and hedge funds have recently made changes to their positions in the business. Tacita Capital Inc bought a new position in shares of Zimmer Biomet during the second quarter valued at about $26,000. Monetary Solutions Ltd bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $30,000. Ancora Advisors LLC purchased a new stake in Zimmer Biomet during the 2nd quarter valued at about $29,000. Elevation Wealth Partners LLC boosted its holdings in Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares during the period. Finally, Cornerstone Financial Management LLC bought a new position in Zimmer Biomet during the 4th quarter worth approximately $37,000. Institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.

Its portfolio also includes orthopedic surgical equipment, robotic- and computer-assisted technologies, biologics and other solutions designed to support joint reconstruction, spine procedures and dental applications.